中文
Products

H-FABP

Quantum Dots-dry fluorescence immunoassay

Intended Use

FABP Rapid Quantitative Test is a fluorescence immunoassay for vitro quantitative measurement of Heart-type Fatty Acid Binding Protein (H-FABP) in human whole blood, serum or plasma It is used for diagnosis of myocardial infarction.

H-FABP

Clinical Department

Internal Medicine-Cardiovascular Department,Clinical lab,ED,ICU,CCU,Pediatric/Neonatology Department,Hematology,Chest pain center,etc.

Product Parameters Clinical application

[Product Name]Human Heart-type Fatty Acid Binding Protein (H-FABP) Detection Kit

[Sample Type]Serum, plasma, and whole blood

[Intended Use]
For the in vitro quantitative detection of Human Heart-type Fatty Acid Binding Protein (H-FABP) in human serum, plasma, or whole blood.

[Clinical Department]
Clinical Laboratory, Ambulance/Emergency Department/ICU/Catheterization Laboratory, Cardiology Department/CCU/Thoracic Surgery Department, Respiratory Medicine Department, Geriatrics Department, etc.

Product Parameters

Item

H-FABP

Test Time

13min

Sample Type

Serum, plasma, and whole blood

Sensitivity

1ng/mL

Storage Condition

4-30℃

Packing Specification

25 Tests/Kit; 50 Tests/Kit

1. Early Diagnosis of Acute Myocardial Infarction (AMI): Combined with cTnI, it achieves higher diagnostic performance.

2. Assessment of Myocardial Infarction Size.

3. Diagnosis and Monitoring of Acute Myocardial Reinfarction.

19.jpg

4. Assessment of Myocardial Ischemia-Reperfusion Efficacy.

5. Risk Stratification of Unstable Angina Pectoris (UAP):

① The higher the H-FABP concentration in UAP patients, the higher the risk level;

② Combined detection of H-FABP and hs-CRP can better predict the risk of short-term cardiovascular events in UAP patients.

6. Risk Stratification of Acute Pulmonary Embolism (APE).

7. Prognostic Assessment of Heart Failure.

8. Clinical Applications in Other Cardiovascular Diseases:

① Can detect early minor myocardial injury in conditions such as heart failure, viral myocarditis, trauma, and sleep apnea syndrome;

② Prognostic assessment of acute pulmonary embolism, chronic thromboembolic pulmonary hypertension, and acute cerebral infarction.


微信公众平台

官网二维码